Apixaban and rivaroxaban safety after hip and knee arthroplasty: A meta-analysis

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 17, Issue 3, 2012, Pages 266-276

  Alves, Carlos ^a,b,c   Batel Marques, Francisco ^a,b   MacEdo, Ana Filipa ^a,c  

^a ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

apixaban; meta analysis; rivaroxaban; safety; thromboprophylaxis

Indexed keywords

APIXABAN; ENOXAPARIN; RIVAROXABAN;

ARTICLE; BLEEDING; DRUG EFFICACY; DRUG SAFETY; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; META ANALYSIS; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SINGLE DRUG DOSE; THROMBOSIS PREVENTION; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM; WOUND COMPLICATION;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; HUMANS; MORPHOLINES; POSTOPERATIVE COMPLICATIONS; PYRAZOLES; PYRIDONES; THIOPHENES; THROMBOSIS;

EID: 84865113005     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248411427402     Document Type: Article

References (44)

1. Warwick D. New concepts in orthopaedic thromboprophylaxis. J Bone Joint Surg Br.. 2004 ; 86 (6). 788-792 (Pubitemid 39173461)
2. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2008 ; 133 (6 suppl). 381S - 453S (Pubitemid 351894916)
3. Hill J, Treasure T. Reducing the risk of venous thromboembolism in patients admitted to hospital: summary of NICE guidance. BMJ. 2010 ; 340: c95
4. Rashid ST, Thursz MR, Razvi NA, et al. Venous thromboembolism in UK medical inpatients. JRSM. 2005 ; 98 (11). 507-512
5. Ginsberg JS, Gent M, Turkstra F, et al. Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study. Arch Intern Med. 2000 ; 160 (5). 669-672 (Pubitemid 30140416)
6. Douketis JD, Eikelboom JW, Quinlan DJ, Willan AR, Crowther MA. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med. 2002 ; 162 (13). 1465-1471 (Pubitemid 34747479)
7. Bjornara BT, Gudmundsen TE, Dahl OE. Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br.. 2006 ; 88 (3). 386-391
8. Seagroatt V, Tan HS, Goldacre M, Bulstrode C, Nugent I, Gill L. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ. 1991 ; 303 (6815). 1431-1435
9. Prevention of venous thrombosis and pulmonary embolism. NIH consensus statement. 1986 ; 6 (2). 1-9
10. Sharrock NE, Gonzalez Della Valle A, Go G, Lyman S, Salvati EA. Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop Relat Res. 2008 ; 466 (3). 714-721 (Pubitemid 351903839)
11. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. American college of chest physicians: parental anticoagulants: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2008 ; 133 (6 suppl). 141S - 159S (Pubitemid 351892966)
12. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 ; 363 (26). 2487-2498
13. Jang IK, Hursting MJ. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation. 2005 ; 111 (20). 2671-2683 (Pubitemid 40740868)
14. Levy JH, Key NS, Azran MS. Novel oral anticoagulants: implications in the perioperative settings. Anesthesiology. 2010 ; 113 (3). 726-745
15. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. American College of Chest Physicians: Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2008 ; 133 (6 suppl). 160S - 198S (Pubitemid 351892967)
16. Weitz JI. New oral anticoagulants in development. Thromb Haemost. 2010 ; 103 (1). 62-70
17. Becattini C, Lignani A, Agnelli G. New oral anticoagulants for the prevention of venous thromboembolism. Drug Des Devel Ther. 2010 ; 4: 49-60
18. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Throm Vasc Biol. 2008 ; 28 (3). 380-386
19. Appraisal Committee Members. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery. NICE technology appraisal guidance 157. 2008. www.nice.org.uk/TA157.
20. Appraisal Committee Members. Rivaroxaban for the prevention of venous thromboembolism after total hip or total replacement in adults. NICE technology appraisal guidance 170. 2009. www.nice.org.uk/TA170.
21. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 ; 361 (6). 594-604
22. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 ; 375 (9717). 807-815
23. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008 ; 358 (26). 2765-2775 (Pubitemid 351930851)
24. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009 ; 373 (9676). 1673-1680
25. Jensen CD, Steval A, Partington PF, Reed MR, Muller SD. Return to theatre following total hip and knee replacement, before and after introduction of rivaroxaban: a retrospective cohort study. J Bone Joint Surg Br.. 2011 ; 93 (1). 91-95
26. Lotke PA. Rivaroxaban for thromboprophylaxis. N Engl J Med. 2008 ; 359 (20). 2174
27. Cao YB, Zhang JD, Shen H, Jiang YY. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2010 ; 66 (11). 1099-1108
28. Gómez-Outes A, Suárez-Gea ML, Blázques-Pérez A, Pozo-Hernández C, Vargas-Castrillón E. Rivaroxaban versus enoxaparin after total knee arthroplasty. Lancet. 2009 ; 374 (9691). 682
29. Johanson NA, Lachiewicz PF, Lieberman JR, et al. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Am Acad Orthop Surg. 2009 ; 17 (3). 183-196
30. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). CHMP assessment report for Xarelto. http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Public-assessment-report/human/000944/WC500057122.pdf. Accessed June 21, 2011.
31. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). CHMP assessment report for Eliquis. http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Public-assessment-report/human/002148/WC500107726.pdf. Accessed June 21, 2011.
32. LokeYKPriceDHerxheimerA. Chapter 14: Adverse effects. In: HigginsJPTGreenS, eds.. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. www.cochrane-handbook.org. Accessed June 21, 2011.
33. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ. 2003 ; 327 (7414). 557-560
34. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 ; 7 (3). 177-188 (Pubitemid 17189972)
35. Introduction to Meta-analysis. Borenstein M Hedges LV Higgins JPT Rothstein HR, ed. Chichester, England: John Wiley & Sons ; 2009: 277-292.
36. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007 ; 5 (12). 2368-2375 (Pubitemid 350154345)
37. Turpie AGG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost.. 2005 ; 3 (11). 2479-2486 (Pubitemid 41727165)
38. Eriksson BI, Borris L, Dahl OE, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006 ; 4 (1). 121-128
39. Eriksson BI, Borris L, Dahl OE, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006 ; 114 (22). 2374-2381 (Pubitemid 44847454)
40. Eriksson BI, Borris L, Dahl OE, et al. Dose-escalation study of rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res. 2007 ; 120 (5). 685-693 (Pubitemid 47268049)
41. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008 ; 372 (9632). 31-39
42. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008 ; 358 (26). 2776-2786 (Pubitemid 351930852)
43. Huang J, Cao Y, Liao C, Wu L, Gao F. Apixaban versus enoxaparin in patients with total knee arthroplasty: a meta-analysis of randomised trials. Thromb Haemost. 2011 ; 105 (2). 245-253
44. Barret YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti- Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010 ; 104 (6). 1263-1271